Blueshift Asset Management LLC Acquires New Stake in Cencora, Inc. (NYSE:COR)

Blueshift Asset Management LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,101 shares of the company's stock, valued at approximately $247,000.

Several other institutional investors have also modified their holdings of COR. Hickory Asset Management Inc. bought a new stake in Cencora in the fourth quarter worth $572,000. Sylvest Advisors LLC bought a new stake in shares of Cencora in the 4th quarter worth about $1,105,000. Insight Wealth Strategies LLC lifted its holdings in shares of Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock worth $4,549,000 after acquiring an additional 11,232 shares during the last quarter. Cerity Partners LLC grew its holdings in Cencora by 10.1% during the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company's stock valued at $8,881,000 after purchasing an additional 3,610 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its position in Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after purchasing an additional 1,995 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,970 shares of company stock valued at $2,998,670. Company insiders own 10.80% of the company's stock.

Remove Ads

Cencora Stock Up 1.1 %

Shares of NYSE:COR traded up $2.84 on Wednesday, reaching $271.32. The company had a trading volume of 1,036,117 shares, compared to its average volume of 1,378,648. The firm has a market capitalization of $52.61 billion, a PE ratio of 38.59, a PEG ratio of 1.31 and a beta of 0.51. The firm's 50 day simple moving average is $251.80 and its 200-day simple moving average is $240.46. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $271.74. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.81%. Cencora's dividend payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on COR. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. JPMorgan Chase & Co. increased their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Wells Fargo & Company boosted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Finally, Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target on the stock. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and a consensus target price of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.